Pieris Pharmaceuticals Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 50

Employees

  • Latest Deal Type
  • M&A

Pieris Pharmaceuticals General Information

Description

Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of the Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store, and transport a wide spectrum of molecules. The Company's clinical pipeline consists of immuno-oncology, or IO, bispecifics in partnership with collaborators, including S095012 (also referred to as PRS-344) targeting PD-L1 and 4-1BB, SGN-BB228 (also referred to as PRS-346) targeting CD228 and 4-1BB, and BOS-342 (also referred to as PRS-342) targeting GPC3 and 4-1BB. Geographically, all the operations of the firm function through the region of the United States.

Contact Information

Website
www.pieris.com
Formerly Known As
Pieris AG
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 225 Franklin Street
  • Floor 26
  • Boston, MA 02110
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Palvella Therapeutics
Vertical(s)
Life Sciences
Corporate Office
  • 225 Franklin Street
  • Floor 26
  • Boston, MA 02110
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pieris Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
15. Merger/Acquisition 13-Dec-2024 Completed Generating Revenue
14. Secondary Transaction - Open Market Completed Generating Revenue
13. PIPE 24-Mar-2021 Completed Generating Revenue
12. Secondary Transaction - Open Market Completed Generating Revenue
11. PIPE 05-Nov-2019 Completed Generating Revenue
10. PIPE 08-Jun-2016 Completed Generating Revenue
9. 2PO 30-Jun-2015 Completed Generating Revenue
8. PIPE 31-Dec-2014 Completed Generating Revenue
7. Reverse Merger 18-Dec-2014 $46.9M Completed Generating Revenue
6. Grant 11-Dec-2014 $7.46M $46.9M Completed Clinical Trials - General
To view Pieris Pharmaceuticals’s complete valuation and funding history, request access »

Pieris Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development
Drug Discovery
Boston, MA
50 As of 2023

Cambridge, United Kingdom
 

Mannheim, Germany
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pieris Pharmaceuticals Competitors (27)

One of Pieris Pharmaceuticals’s 27 competitors is Bicycle Therapeutics, a Formerly VC-backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Bicycle Therapeutics Formerly VC-backed Cambridge, United Kingdom
Affimed Formerly VC-backed Mannheim, Germany
Alligator Bioscience Formerly VC-backed Lund, Sweden
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Molecular Partners Formerly VC-backed Zurich, Switzerland
You’re viewing 5 of 27 competitors. Get the full list »

Pieris Pharmaceuticals Patents

  • 461

    Total Documents Applications and Grants

  • Total Patents Families

  • 218

    Granted

  • 23

    Pending

  • Expiring in next 12 mo

Pieris Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023347921-A1 Novel fusion protein specific for cd137 and cd228 Pending 21-Sep-2022
EP-4590695-A1 Novel fusion protein specific for cd137 and cd228 Inactive 21-Sep-2022
WO-2024064713-A1 Novel fusion protein specific for cd137 and cd228 Inactive 21-Sep-2022
WO-2023180523-A1 Process for purifying fusion proteins Inactive 24-Mar-2022
WO-2023180523-A9 Process for purifying fusion proteins Inactive 24-Mar-2022 C07K14/435
To view Pieris Pharmaceuticals’s complete patent history, request access »

Pieris Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pieris Pharmaceuticals Former Investors (21)

Investor Name Investor Type Holding Investor Since Participating Rounds
Ally Bridge Group Growth/Expansion Minority
BayTech Venture Capital Venture Capital Minority
Bayern Kapital Venture Capital Minority
BioM Biotech Cluster Development Accelerator/Incubator Minority
Citadel Enterprise Americas Hedge Fund Minority
You’re viewing 5 of 21 investors. Get the full list »

Pieris Pharmaceuticals Acquisitions (2)

Pieris Pharmaceuticals’s most recent deal was a Reverse Merger with Palvella Therapeutics. The deal was made on 12-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Palvella Therapeutics 12-Dec-2024 Reverse Merger Drug Discovery
Marikaaa 18-Dec-2014 Merger/Acquisition Media and Information Services (B2B)
To view Pieris Pharmaceuticals’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Pieris Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Pieris Pharmaceuticals’s complete esg history, request access »

Pieris Pharmaceuticals FAQs

  • When was Pieris Pharmaceuticals founded?

    Pieris Pharmaceuticals was founded in 2001.

  • Where is Pieris Pharmaceuticals headquartered?

    Pieris Pharmaceuticals is headquartered in Boston, MA.

  • What is the size of Pieris Pharmaceuticals?

    Pieris Pharmaceuticals has 50 total employees.

  • What industry is Pieris Pharmaceuticals in?

    Pieris Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Pieris Pharmaceuticals a private or public company?

    Pieris Pharmaceuticals is a Private company.

  • What is Pieris Pharmaceuticals’s current revenue?

    The current revenue for Pieris Pharmaceuticals is .

  • How much funding has Pieris Pharmaceuticals raised over time?

    Pieris Pharmaceuticals has raised $173M.

  • Who are Pieris Pharmaceuticals’s investors?

    Ally Bridge Group, BayTech Venture Capital, Bayern Kapital, BioM Biotech Cluster Development, and Citadel Enterprise Americas are 5 of 21 investors who have invested in Pieris Pharmaceuticals.

  • Who are Pieris Pharmaceuticals’s competitors?

    Bicycle Therapeutics, Affimed, Alligator Bioscience, CytomX Therapeutics, and Molecular Partners are some of the 27 competitors of Pieris Pharmaceuticals.

  • When was Pieris Pharmaceuticals acquired?

    Pieris Pharmaceuticals was acquired on 13-Dec-2024.

  • Who acquired Pieris Pharmaceuticals?

    Pieris Pharmaceuticals was acquired by Palvella Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process